Evidence map›Paper›PMID 41209698›Full record

ArticleMaterials today. Bio2025

Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy.

Fang Cui, Qi-Xin Huang, Zhuo Yu, Jin-Ju Yang, Shi-Yu Liang, Mei-Qi Wang, Jie Zhu, Chen Tian, Shao-Xun Li, Hao-Tian Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fang CuiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Qi-Xin HuangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Zhuo YuState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Jin-Ju YangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Shi-Yu LiangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Mei-Qi WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Jie ZhuState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Chen TianState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Shao-Xun LiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Hao-Tian WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Fei ChenState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Yang-Jie LiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Xiaobin FengYtrrium-90 Precision Interventional Radiotherapy Center of Liver Cancer, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China.
Rui-Tian LiuState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Lingxiao ZhangSchool of Medicine, Hangzhou City University, Hangzhou, 310015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with limited effective therapeutic options. While trace elements like selenium (Se)-based nanoparticles (SeNPs) show promising anti-tumor effects, their clinical application is greatly hindered by poor targeting efficiency. Here, we engineered a biomimetic Se nanomedicine, CCEVSe, by encapsulating SeNPs within tumor cell-derived extracellular vesicles (CCEVs). Utilizing the inherent homotypic targeting and immune-evasion properties of CCEVs, CCEVSe selectively targets and is effectively internalized by tumor cells of the same origin.

Indexed as

Biomimetic nanomedicineExtracellular vesiclesHepatocellular carcinomaHomotypic targetingSelenium nanoparticles

Identifiers

PMID41209698
PMCPMC12593715

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.